These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29127458)

  • 1. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.
    Schwabe C; Rosenstock B; Doan T; Hamilton P; Dunbar PR; Eleftheraki AG; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    J Clin Pharmacol; 2018 Dec; 58(12):1566-1577. PubMed ID: 30113724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.
    Visvanathan S; Daniluk S; Ptaszyński R; Müller-Ladner U; Ramanujam M; Rosenstock B; Eleftheraki AG; Vinisko R; Petříková A; Kellner H; Dokoupilova E; Kwiatkowska B; Alten R; Schwabe C; Baum P; Joseph D; Fine JS; Padula SJ; Steffgen J
    Ann Rheum Dis; 2019 Jun; 78(6):754-760. PubMed ID: 30902820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
    Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
    Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody.
    Espié P; He Y; Koo P; Sickert D; Dupuy C; Chokoté E; Schuler R; Mergentaler H; Ristov J; Milojevic J; Verles A; Groenewegen A; Auger A; Avrameas A; Rotte M; Colin L; Tomek CS; Hernandez-Illas M; Rush JS; Gergely P
    Am J Transplant; 2020 Feb; 20(2):463-473. PubMed ID: 31647605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M
    Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis.
    Zhang L; Zhang W; Xu Y; Dong L; Sun Y; Jia Y; Li Z; Chen B; Hou J; Zhang J
    Adv Ther; 2024 Jul; 41(7):2953-2965. PubMed ID: 38833140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
    Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
    Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study.
    Cao G; Yang H; Wang J; Ishida M; Thoma C; Haeufel T; Bossert S; Zhang J
    Adv Ther; 2024 Sep; 41(9):3557-3568. PubMed ID: 39039387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
    Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects.
    Khalilieh S; Hodsman P; Xu C; Tzontcheva A; Glasgow S; Montgomery D
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):294-300. PubMed ID: 29510001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response.
    Samant M; Ziemniak J; Paolini JF
    J Pharmacol Exp Ther; 2023 Dec; 387(3):306-314. PubMed ID: 37699709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.
    Meininger V; Pradat PF; Corse A; Al-Sarraj S; Rix Brooks B; Caress JB; Cudkowicz M; Kolb SJ; Lange D; Leigh PN; Meyer T; Milleri S; Morrison KE; Orrell RW; Peters G; Rothstein JD; Shefner J; Lavrov A; Williams N; Overend P; Price J; Bates S; Bullman J; Krull D; Berges A; Abila B; Meno-Tetang G; Wurthner J
    PLoS One; 2014; 9(5):e97803. PubMed ID: 24841795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.
    White B; Leon F; White W; Robbie G
    Clin Ther; 2009 Apr; 31(4):728-40. PubMed ID: 19446146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
    McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
    Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers.
    Staton TL; Peng K; Owen R; Choy DF; Cabanski CR; Fong A; Brunstein F; Alatsis KR; Chen H
    BMC Pulm Med; 2019 Jan; 19(1):5. PubMed ID: 30616547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
    Portron A; Jordan P; Draper K; Muenzer C; Dickerson D; van Iersel T; Hofmann C
    Clin Ther; 2020 Jan; 42(1):108-120.e1. PubMed ID: 31883703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.
    Emu B; Luca D; Offutt C; Grogan JL; Rojkovich B; Williams MB; Tang MT; Xiao J; Lee JH; Davis JC
    Arthritis Res Ther; 2012 Jan; 14(1):R6. PubMed ID: 22225620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.